2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia
- 30 April 2003
- journal article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 30 (2), 243-247
- https://doi.org/10.1053/sonc.2003.50070
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory diseaseBlood, 2001
- Waldenström’s Macroglobulinemia: Clinical Features, Complications, and ManagementJournal of Clinical Oncology, 2000
- Fludarabine treatment in resistant Waldenstrom's macroglobulinemiaEuropean Journal of Haematology, 1995
- Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.Journal of Clinical Oncology, 1994
- Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utilityBlood, 1994
- Waldenstrom's macroglobulinemiaBlood, 1994
- Fludarabine therapy in Waldenström's macroglobulinemiaAmerican Journal Of Medicine, 1993
- Treatment of Waldenstrom Macroglobulinemia with 2-ChlorodeoxyadenosineAnnals of Internal Medicine, 1993
- Waldenström's Macroglobulinemia: Long-Term Results with the M-2 ProtocolCancer Investigation, 1991
- Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patientsJournal of Internal Medicine, 1989